Acute Kidney Injury Clinical Trial
Official title:
Epidemiology of Acute Kidney Injury in England - 1998 to 2013
The true population incidence of acute kidney injury (AKI), previously called acute renal failure, in England is not known. A better understanding of the epidemiology of AKI at a national level is essential to inform initiatives to prevent AKI as well as reduce the associated morbidity and mortality. The purpose of this study is to combine the national database of all hospital discharges with national census data to investigate trends in the incidence of both, AKI not requiring dialysis and AKI requiring dialysis, as well as its associated mortality and its determinants in England between 1998 and 2013
Subject Selection and Withdrawal We will identify all cases of AKI by using validated
International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)
codes in any of he diagnoses codes, in keeping with the objective of the study. Patients
with any of the following codes will be included: N17.0 for acute renal failure with tubular
necrosis, N17.1 for acute renal failure with acute cortical necrosis, N17.2 for acute renal
failure with medullary necrosis, N17.8 for other acute renal failure and N17.9 for acute
renal failure, unspecified. Acute renal failure has been replaced by new terminology, acute
kidney injury, but due to lack of ICD-10-CM codes for AKI, we will use the ICD-10-CM codes
for acute renal failure and henceforth, will be referred to as AKI in this protocol.
Subject Recruitment and Screening We will extract 1998 to 2013 data from the Hospital
Episode Statistics (HES), a data warehouse containing details of all admissions, outpatient
appointments and A&E attendances at National Health Service (NHS) hospitals in England. HES
collects a detailed record for each 'episode' of admitted patient care delivered in England,
either by NHS hospitals, primary care trusts, mental health trusts or delivered in the
independent sector but commissioned by the NHS. These data are collected during a patient's
time in hospital and stored as a large collection of separate records, one for each period
of care, in a secure data warehouse. We will extract secondary diagnosis codes for up to 14
diagnoses available till 2006-07 and up to 20 additional diagnoses from 2007 till 2013. In
addition to demographic data, we will also extract up to 15 procedure codes. To identify AKI
patients requiring dialysis, we will include procedure code of X40.3 for hemodialysis or
X40.4 for hemofiltration in any of the 15 procedures. To exclude patients with chronic
kidney disease starting dialysis, we will exclude patients who had chronic kidney disease
(CKD) stage 5 (N18.5) and end stage renal disease (N18.6) and procedure codes for
arteriovenous fistula (L74.2) or arteriovenous shunt (L74.3) during the inpatient admission
(figure 1). This algorithm has been shown to be sensitive and specific, with a high positive
and negative predictive value (all >90%. Patients who were admitted, but were not discharged
during the study period will not be included in the study.
We will obtain data on patient demographics, hospital characteristics, in-hospital
mortality, disposition, length of stay (LOS), and up to 20 diagnosis and 15 procedure codes
that are based on the ICD-10-CM and Office of Population Censuses and Surveys Classification
of Surgical Operations and Procedures, 4th revision (OPCS-4) from the HES database. To
obtain population incidence of AKI requiring dialysis, we will obtain mid-year populations
of England in each year from 1998 to 2013 from the Office of National Statistics (ONS). We
will also obtain length of stay and mortality for all patients who did not have acute kidney
injury coded as N17 in any of the diagnoses codes, in England over the same time period.
Patients will not be contacted. This study will not obtain informed consent from the
patients' as we will be working with anonymous patient data. No screening requirements
(laboratory or diagnostic testing) are necessary to meet the inclusion or exclusion
criteria. Unique Subject Identification numbers are already allocated to the patients and
the HES database does not include any patient's name or hospital number.
Sample Size Determination The data from HES will be extracted for the period between April
1998 and March 2013. HES data is collected during a patients' time at hospital and is
submitted to allow hospitals to be paid for the care they deliver. As this is a
retrospective population cohort study using a national database, all cases of AKI as defined
by the inclusion criteria, from the HES database will be used.
Statistical Methods All analyses will be performed using validated statistical software.
Data during the 15-year period will be divided into three 5-yr periods (April 1988 to March
2003, April 2003 to March 2008 and April 2008 to March 2013) and also presented by
individual year. Age will be categorized into the groups <65, 65-74, 75-84 and>85. Charlson
scores greater than 5 will be grouped into one category. Method of admission will be defined
as one of elective admission; emergency admission; maternity admission; other admission or
unknown. Ethnicity will be grouped as White, Mixed, Asian, Black, other ethnic groups and
ethnicity not stated/unknown.
Continuous variables will be expressed as mean with 95% confidence interval (CI).
Categorical variables will be expressed as proportions and compared with the chi square
test. Incidence rates per 1000 person-years and 95% confidence intervals will be calculated
using Poisson regression analysis and compared using a chi-squared test for proportions.
Age-adjusted incidence rates for AKI will be calculated based on the UK standard population
using the direct standardization method. Further analysis will be done to identify regional
variation in epidemiology of both AKI not requiring dialysis and AKI requiring dialysis in
England.
The Poisson regression model will be used to analyse the effect of gender, age group, period
of admission, method of admission, Charlson co-morbidity index and ethnicity on incidence of
AKI. Cox Proportional Hazard Models will be applied to test the association between
mortality and these variables. Multivariable logistic regression will be considered to
assess the association between AKI and all these variables simultaneously. We will use the
middle period of 2003-2008 as reference, which will enable us to evaluate improvement in
mortality as compared to 1998-2003 and also to evaluate whether the improvement has been
sustained in the later period of 2008-2013. The effect of AKI on mortality and length of
stay will be tested using the Cox Proportional Hazard Models and the Linear Regression
respectively. Long-term survival of patients will be plotted using Kaplan Meir curves after
obtaining the date and cause of death for all patients obtained from Office of National
Statistics.
We will randomly select a number of patients who had a recorded diagnosis of AKI in HES
database since 1998. Controls will also be selected and matched to each patient by age, sex,
date of diagnosis and region. The association between AKI and each exposure will be analyzed
using conditional logistic regression.
Data Handling and Record Keeping The data obtained from HES will be anonymised and will not
have any patient identifiable characteristics. The study protocol, documentation, data and
all other information generated will be held in strict confidence. No information concerning
the study or the data will be released to any unauthorized third party, without prior
written approval of the sponsoring institution. Authorized representatives of the sponsoring
institution may inspect all documents and records, required to be maintained, by the
Investigator, including but not limited to, medical records (office, clinic or hospital) for
the subjects in this study. The clinical study site will permit access to such records.
Information about study subjects will be kept confidential and managed according to the
requirements of the Data Protection Act, NHS Caldicott Guardian, The Research Governance
Framework for Health and Social Care, Ethics Committee Approval and Trust IM&T Policy. The
Chief/Principal Investigator will be the "Custodian" of the data
Source Documents The source document will be the HES database. HES data is held as financial
year data-sets, although the source data is collected monthly from NHS - and originates from
commissioning messages sent by healthcare providers to healthcare commissioners via the
secondary User Services (SUS). At pre-arranged date during the year, SUS takes an extract
from their database and sends it to HES. HES then validates and clean the extract, before
deriving new items and making the information available in the data warehouse. Data quality
reports and checks are completed at various stages in the cleaning and processing cycle.
Records Retention The data will be kept for 15 years after the completion of the study, in
accordance with the requirements of the Therapeutic Goods Administration and Health Privacy
Principals.
All research data and study related documents will be stored, following the end of the
study. The data will be secured in password-protected computer with access to the chief
investigator. The data will be deleted from the hard drive of the computer at the end of the
archival period.
Study Monitoring, Auditing, and Inspecting The investigator will permit study-related
monitoring, audits and inspections by the Ethics Committee, the Sponsor and the Research
Governance Manager. This study will be monitored by the Research Governance Manager
according to the Research & Development Office procedure for monitoring all non-commercial
research carried out at the Derby Hospitals NHS Foundation Trust and the Southern Derbyshire
Primary Care Trusts. In line with the responsibilities set out in the Research Governance
Framework, the Investigator will ensure that the research governance manager or other
regulatory monitoring authority is given access to all study-related documents and study
related facilities.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
| Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
| Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
| Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
| Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
| Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
| Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
| Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
| Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
| Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
| Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
| Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
| Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
| Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
| Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
| Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
| Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
| Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
| Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |